Back

Drug screening identifies the Src/Abl inhibitor Dasatinib as suppressor of IL-23 signalling in skin inflammation

Navarro, M. N.; Valle-Pastor, M. J.; Cayuela, I.; Yebra, J. S.; Senach-Rasilla, L.; Pastor-Fernandez, G.; Oliva, A.; Traba, J.

2025-12-08 immunology
10.64898/2025.12.04.692333 bioRxiv
Show abstract

IL-23-driven IL-17 production by {gamma}{delta}17 and Th17 cells is central to the pathogenesis of psoriasis and other autoimmune disorders. The intracellular mechanisms linking IL-23 signalling to effector cytokine production remain incompletely defined and thus, therapeutic targets downstream of IL-23 are limited. Here, we developed an in vitro model based on a {gamma}{delta}17 T cell line to study IL-23 responses and identify pharmacological inhibitors of type 3 immunity. We conducted a drug-repurposing screening of FDA-approved compounds and identified Src/Abl kinase inhibitors Dasatinib and Bosutinib as potent suppressors of IL-23-induced IL-17A production. In vivo, intraperitoneal and topical Dasatinib administration reduced epidermal thickening, immune cell infiltration, and the accumulation of IL-17-producing T cells in the Imiquimod model of skin inflammation. Mechanistically, Dasatinib and Bosutinib blocked IL-23-dependent mTORC1 and mTORC2 activation. Finally, loss-of-function experiments identified the Src kinase Blk as a critical mediator of IL-23-induced mTORC1 activation and IL-17A production in {gamma}{delta}17 T cells. These findings uncover a novel IL-23-Src-mTOR axis in type 3 immunity, opening the door for therapeutic targeting of Src signalling networks in IL-23/IL-17-driven inflammation.

Published in Journal of Allergy and Clinical Immunology (predicted rank #17) · training set

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.